肝疾患治療市場：肝疾患タイプ、治療タイプ、地域別、2026～2032年

肝疾患治療市場の評価-2026～2032年

肝疾患の世界の有病率の増加は、生活習慣の悪化、アルコール摂取、ウイルス性肝炎感染の増加などの要因によってもたらされています。これらの疾患の悪化に伴い、肝臓疾患を管理・治療するための効果的な治療法の必要性が高まっています。ヘルスケアインフラの拡大と新興国における医療費の増加は、肝疾患に対する改善された治療や治療法へのアクセスを向上させ、市場拡大を後押ししています。2024年には160億9,000万米ドル、2032年には390億4,000万米ドルに達します。

さらに、医療研究と技術の進歩により、肝疾患の治療結果の改善や未充足の医療ニーズに対応する可能性を秘めた、標的生物製剤や遺伝子療法などの革新的な医薬品の開発が進んでいます。2026年から2032年までの期間において、この市場は年平均成長率（CAGR）約11.72%で成長すると予測されています。

肝疾患治療市場定義/概要

肝疾患治療には、肝炎、脂肪肝、肝硬変、肝がんなどの肝疾患を管理・治療するための治療や薬剤が含まれます。抗ウイルス薬、免疫抑制剤、肝移植術は、利用可能な治療法の一つです。治療現場でのこれらの応用には、病気の発症を避け、症状をコントロールし、患者のQOLを高めることが含まれます。肝疾患治療の将来は楽観視できそうで、有効性の向上と副作用の軽減を目指し、標的治療、個別化医療、再生治療の開発に焦点を当てた研究が続けられており、最終的には世界中で患者の転帰が改善されることになります。

肝疾患の有病率の上昇は肝疾患治療市場を促進するか？

肝疾患の有病率の上昇は、肝疾患治療市場を大きく牽引すると予測されています。肝疾患には、ウイルス性肝炎、非アルコール性脂肪性肝疾患（NAFLD）、アルコール性肝疾患、肝硬変、肝がんなどが含まれます。最近の政府統計によると、肝臓疾患は世界の健康問題になっています。世界保健機関（WHO）によると、肝疾患は2023年までに年間200万人近くを死亡させるといいます。

2024年、米国疾病予防管理センター（CDC）は、慢性肝疾患と肝硬変が米国における第9位の死因であり、年齢調整死亡率は人口10万人当たり13.5人であると報告しました。

世界中の政府もまた、肝臓疾患の有病率の増加に対処するため、積極的な措置を講じています。肝疾患の発生と進行を抑えるため、生活習慣の改善を提唱する公衆衛生キャンペーン、肝炎ウイルス予防接種プログラム、アルコール削減施策などが導入されています。これらの活動は、規制状況を変化させ、肝疾患治療の商業的成長を促進する上で極めて重要です。2024年1月、英国の国民保健サービス（NHS）は、肝疾患の早期発見とヘルスケアシステムへの負担軽減を目的として、全国規模の肝臓健康診断プログラムを開始しました。

肝疾患治療市場の将来は明るいと思われ、精密医療法や標的治療に集中した継続的な研究が行われています。遺伝子編集技術やバイオマーカーの発見といったバイオテクノロジーの革新は、肝臓疾患患者の治療戦術を変革し、オーダーメイドでより効果的な解決策を提供する可能性が高いです。2024年2月、スタンフォード大学の研究者たちはネイチャー誌に画期的な紙製を発表し、NAFLDからより重篤な肝疾患への進行を予測できる遺伝子マーカーを明らかにしました。

薬剤耐性に対する懸念の高まりは肝疾患治療市場の成長を妨げるか？

肝疾患の有病率の増加は、肝疾患治療市場を急増させると予測されています。薬剤耐性とは、ウイルスや細菌などの微生物が、治療に使用する薬剤に対して耐性を獲得し、現在の治療効果を低下させることです。肝疾患、特にウイルス性肝炎では、B型肝炎ウイルス（HBV）やC型肝炎ウイルス（HCV）のような薬剤耐性株の増加が大きな障害となっています。これらの耐性株は治療の選択肢を狭め、治療の失敗を引き起こし、病気の進行を悪化させ、ヘルスケア支出を増加させています。

最近の調査では、肝炎ウイルスにおける薬剤耐性の発生が証明されています。例えば、B型肝炎では、抗ウイルス薬の長期投与によって耐性変異が形成され、ウイルスの繁殖を阻害するために日常的に使用されているヌクレオシド（t）イデアナログの効率が低下する可能性があります。同様に、C型肝炎に対する直接作用型抗ウイルス薬（DAA）が利用可能であるにもかかわらず、耐性変異の報告があり、厳重なモニタリングと場合によっては治療レジメンの変更が必要です。

製薬会社や学術機関は、薬剤耐性に対抗するための新規抗ウイルス薬や併用療法の研究に積極的に取り組んでいます。しかし、このような取り組みには高額な費用と長い開発スケジュールがかかるため、経済的な懸念があります。さらに、規制機関には安全性と有効性を示すための厳しい要件があり、新しい治療法の市場参入を複雑にしています。

政府やヘルスケアグループは、薬剤耐性と闘うための予防イニシアチブにも取り組んでいます。これには、肝炎ウイルスワクチンの推進、早期発見スクリーニングプログラムの構築、治療プロトコールの遵守に関するヘルスケア従事者と患者のトレーニングなどが含まれます。しかし、薬剤耐性と闘うには、調査、サーベイランス、ヘルスケアインフラへの継続的な投資が必要であり、ヘルスケア予算やリソースを圧迫する可能性があります。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主要調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 肝疾患治療市場：肝疾患タイプ別

• 肝炎
• 非アルコール性脂肪性肝疾患（NAFLD）
• アルコール性肝疾患（ALD）
• 肝硬変
• 肝がん（肝細胞がん）

第5章 肝疾患治療市場：治療タイプ別

• 薬剤療法
• 肝移植
• 栄養と生活習慣への介入
• インターベンション

第6章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第7章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第8章 競合情勢

• 主要企業
• 市場シェア分析

第9章 企業プロファイル

• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Gilead Sciences, Inc.
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Novartis AG
• Johnson & Johnson
• Celgene Corporation
• Samsung Bioepis Co., Ltd.

第10章 市場展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第11章 市場展望付録

• 略語リスト
• 供給源と参考文献

Liver Diseases Therapeutics Market Valuation - 2026-2032

The increasing global prevalence of liver illnesses is being driven by factors such as poor lifestyles, alcohol consumption, and an increase in viral hepatitis infections. As these disorders worsen, there is a greater need for effective therapies to manage and treat liver illnesses. Expanding healthcare infrastructure and rising healthcare expenditure in emerging countries help to drive market expansion by improving access to improved treatments and therapies for liver diseases. USD 16.09 Billion in 2024 and reaching USD 39.04 Billion by 2032.

Furthermore, advances in medical research and technology are resulting in the development of innovative medicines, such as targeted biologics and gene therapies, which show promise for improving treatment results and addressing unmet medical requirements in liver disease management growth is expected to grow at a CAGR of about 11.72% from 2026-2032.

Liver Diseases Therapeutics Market: Definition/ Overview

Liver disease therapeutics include treatments and drugs for managing and curing liver illnesses such as hepatitis, fatty liver disease, cirrhosis, and liver cancer. Antiviral medications, immunosuppressants, and liver transplant procedures are among the available treatments. Their applications in therapeutic settings include avoiding disease development, controlling symptoms, and increasing patient quality of life. The future of liver disease therapeutics seems optimistic, with continuing research focusing on creating targeted medications, personalized medicine methods, and regenerative treatments that aim to improve efficacy and reduce adverse effects, ultimately improving patient outcomes worldwide.

Will Rising Prevalence of Liver Disorders Propel the Liver Diseases Therapeutics Market?

The rising prevalence of liver disorders is predicted to considerably drive the Liver disorders Therapeutics Market. Liver diseases include viral hepatitis, nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease, cirrhosis, and liver cancer. According to recent government figures, liver illnesses are becoming a major global health concern. According to the World Health Organization (WHO), liver disorders will kill nearly 2 million people annually by 2023.

In 2024, the Centers for Disease Control and Prevention (CDC) reported that chronic liver disease and cirrhosis were the ninth largest cause of death in the United States, with an age-adjusted death rate of 13.5 per 100,000 people.

Governments around the world are also taking aggressive steps to address the increased prevalence of liver ailments. To reduce the incidence and progression of liver disease, public health campaigns advocating lifestyle modifications, hepatitis virus immunization programs, and alcohol-reduction policies are being introduced. These activities are critical for changing the regulatory landscape and driving commercial growth for liver disease therapies. In January 2024, the UK's National Health Service (NHS) launched a nationwide liver health screening program, with the goal of detecting liver disorders at an earlier stage and reducing the strain on the healthcare system.

The future of the liver diseases therapeutics market appears bright, with continuous research concentrating on precision medicine methods and targeted therapeutics. Biotechnology innovations, such as gene editing techniques and biomarker discoveries, are likely to transform therapy tactics for people with liver illnesses, providing tailored and more effective solutions. Collaboration among governments, healthcare providers, and pharmaceutical companies is critical in driving progress and assuring access to quality care, ultimately improving outcomes and lowering the global burden of liver disorders. in February 2024, Stanford University researchers released a groundbreaking paper in Nature, revealing a collection of genetic markers that can predict the progression of NAFLD to more severe forms of liver disease, opening the door to tailored treatment techniques.

Will Growing Fears Regarding Drug Resistance Hamper the Growth of the Liver Diseases Therapeutics Market?

Growing prevalence of liver diseases is projected to upsurge the liver diseases therapeutics market. Drug resistance occurs when microorganisms, such as viruses or bacteria, develop resistance to the medications used to treat them, lowering the efficacy of current therapy. In the context of liver illnesses, particularly viral hepatitis, the rise of drug-resistant strains like hepatitis B virus (HBV) and hepatitis C virus (HCV) presents considerable hurdles. These resistant strains can limit treatment options and cause treatment failures, aggravating disease progression and driving up healthcare expenditures.

Recent research has demonstrated the incidence of medication resistance in hepatitis viruses. For instance, in hepatitis B, extended antiviral medication might result in the formation of resistance mutations, lowering the efficiency of nucleos(t)ide analogs routinely employed to inhibit viral reproduction. Similarly, despite the availability of direct-acting antiviral (DAA) medicines for hepatitis C, there have been reports of resistance mutations, needing close monitoring and possibly treatment regimen changes.

Pharmaceutical companies and academic organizations are aggressively researching novel antiviral medicines and combination therapies to combat medication resistance. However, the high expenses and long development schedules connected with these initiatives provide economic concerns. Furthermore, regulatory bodies have strict requirements for showing safety and efficacy, complicating the entry of new therapies to the market.

Governments and healthcare groups are also working on prevention initiatives to combat medication resistance. These include promoting hepatitis virus vaccine, creating early detection screening programs, and training healthcare practitioners and patients on treatment protocol adherence. However, combating drug resistance necessitates ongoing investment in research, surveillance, and healthcare infrastructure, which may strain healthcare budgets and resources.

Category-Wise Acumens

Will Rising Prevalence of Hepatitis Worldwide the Liver Diseases Therapeutics Market?

The increasing frequency of hepatitis worldwide is expected to have a substantial impact on the Liver Diseases Therapeutics Market. Hepatitis, particularly hepatitis B and C viruses (HBV and HCV), is still a serious global health concern, impacting millions of people. According to a WHO research, immunization, diagnostic tests, medicines, and information campaigns could avert approximately 4.5 million premature deaths in low- and middle-income countries by 2030. WHO's global hepatitis plan, which is supported by all WHO Member States, seeks to reduce new hepatitis infections by 90% and fatalities by 65% between 2016 and 2030.

Recent advancements in the pharmaceutical industry highlight substantial progress in combating hepatitis. For instance, in June 2023, AbbVie published encouraging findings from a phase 3 trial of its innovative pan-genotypic hepatitis C therapy, which demonstrated high efficacy rates across many patient populations. This study highlights ongoing attempts to improve treatment options and efficacy in battling hepatitis C, a key contributor to the liver diseases therapeutics Market.

Governments and international health organizations are also stepping up efforts to prevent hepatitis through comprehensive public health policies. The World Health Organization (WHO) has set lofty goals for ending viral hepatitis as a public health issue by 2030. These activities include increasing access to cheap diagnostic equipment, treatments, and vaccines, as well as supporting preventative measures including safe injection practices and hepatitis B vaccination programs.

Meanwhile, the most rapidly developing categories are non-alcoholic fatty liver disease (NAFLD) and its advanced version, non-alcoholic steatohepatitis (NASH). The global rise in obesity and metabolic syndrome has resulted in an increased incidence of NAFLD/NASH, which is projected to boost demand for treatments that target these disorders. Alcoholic Liver Disease (ALD), Liver Cirrhosis, and Liver Cancer (Hepatocellular Carcinoma) are also substantial market sectors, owing to developments in treatment options and increasing awareness, particularly in regions with high alcohol consumption and hepatitis prevalence.

Will Increasing Adoption of Pharmacotherapy Propel the Liver Diseases Therapeutics Market?

The growing use of pharmacotherapy is likely to boost the liver diseases therapeutics market significantly. Pharmacotherapy, which includes antivirals, immunosuppressants, and chemotherapeutic drugs, is essential in the treatment of a variety of liver illnesses, including hepatitis, non-alcoholic fatty liver disease (NAFLD), and liver cancer. In 2023 According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), pharmaceutical therapies will be used to manage more than 60% of patients with chronic liver disease. This shift is being driven by the advancement of more effective and tailored drugs that can halt disease progression, manage symptoms, and, in some cases, reverse liver damage.

Governments around the world are increasingly emphasizing healthcare investments to combat liver illnesses. In the Asia-Pacific area, governments are adopting comprehensive immunization programs and treatment measures to eradicate hepatitis and reduce disease burden, which is driving up market demand for pharmacotherapy. In March 2024, Gilead Sciences received FDA clearance for a novel combination medication for chronic hepatitis B, which is estimated to earn over $1 billion in annual sales by 2026.

Meanwhile, interventional procedures are the fastest increasing area, thanks to advances in minimally invasive approaches for treating liver tumors and cirrhosis problems such as radiofrequency ablation, transarterial chemoembolization (TACE), and selective internal radiation therapy (SIRT). These techniques offer effective therapeutic alternatives, reducing recovery periods and increasing patient outcomes, resulting in increased acceptance in clinical practice. Nutritional and lifestyle interventions, as well as liver transplantation, continue to play an important role in the market, focusing on disease prevention, management, and increasing patient survival rates.

Country/Region-wise

Will Rising Advanced Healthcare Infrastructure in North America Drive the Liver Diseases Therapeutics Market?

The growing modern healthcare infrastructure in North America is expected to drive significant growth in the liver diseases therapeutics market. The region's well-established healthcare systems, combined with significant investments in medical R&D, foster innovation and adoption of innovative therapies. Recent figures highlight North America's robust healthcare expenditure, which helps to develop and implement cutting-edge liver disease therapies.

In recent years, North America has seen significant advances in liver disease treatment. For instance, in October 2023, AbbVie announced FDA clearance for their novel hepatitis C treatment regimen, which combines two direct-acting antivirals (DAAs) with different modes of action. This approval underscores continuous efforts in the region to improve treatment efficacy and patient outcomes. Such developments profit from shipments benefit from North America's strict regulatory environment and advanced healthcare infrastructure, which allow for fast approvals and widespread uptake of new therapies.

Furthermore, the region's emphasis on precision medicine and individualized therapeutics is changing the face of liver disease therapy. For instance, in March 2024, Regeneron Pharmaceuticals reported positive Phase 3 findings for a genetically targeted medication for a subpopulation of non-alcoholic steatohepatitis (NASH) patients, with a 40% improvement in liver fibrosis compared to usual care. This news resulted in a 15% increase in the company's stock price, demonstrating the market's enthusiasm for precision methods to liver disease therapy.

Will Rising Healthcare Expenditure in Asia-Pacific Boost the Liver Diseases Therapeutics Market?

Rising healthcare expenditure in the Asia-Pacific region is predicted to significantly enhance the liver diseases therapeutics market. As Asia-Pacific economies grow, so does healthcare spending, with the goal of enhancing healthcare infrastructure, expanding access to medical services, and tackling the rising burden of chronic diseases, such as liver disease. Recent figures show significant investments in healthcare across the region, emphasizing the potential for market growth in liver disease therapies.

For instance, in recent years, countries such as China and India have seen significant rises in healthcare spending. In July 2023, China announced intentions to invest around USD 2.3 Trillion yuan (approximately USD 360 Billion USD) in healthcare reforms over the following few years, with a focus on expanding medical services and implementing innovative therapies. Similarly, India has increased healthcare investments, including steps to strengthen healthcare infrastructure and enhance access to critical drugs and treatments.

These efforts are critical in addressing Asia-Pacific's rising liver disease prevalence. Hepatitis, particularly hepatitis B and C, is a major health concern in the region. Recent company news emphasizes advances in therapy options to combat severe disorders. For instance, in September 2023, Gilead Sciences published favorable clinical trial findings for its new hepatitis C drug, which showed high efficacy and safety profiles in Asian populations. These advancements demonstrate the pharmaceutical industry's dedication to fulfilling the region's healthcare needs while also driving market growth in liver disease therapies.

Furthermore, regulatory reforms and policies that promote healthcare innovation are helping industry growth. Countries in Asia-Pacific are streamlining regulatory processes to speed up the approval and adoption of novel cures, increasing market competitiveness and promoting investment in R&D. These initiatives are intended to provide a favorable environment for pharmaceutical companies to introduce new medicines and increase their market position in liver disease therapy.

Competitive Landscape

The competitive landscape of the liver diseases therapeutics market is characterized by intense research and development activities aimed at advancing treatment options for various liver conditions. The numerous pharmaceutical companies, biotechnology firms, and academic institutions are actively involved in developing novel therapies and enhancing existing treatments. Regulatory approvals and clinical trials play a crucial role in shaping market dynamics, with companies focusing on differentiated approaches such as personalized medicine, targeted therapies, and immunomodulatory drugs to address the diverse needs of patients. Additionally, collaborations between industry players and healthcare providers contribute to the expansion of treatment options and the improvement of patient outcomes in this competitive market segment.

Some of the prominent players operating in the liver diseases therapeutics market include:

• AbbVie, Inc.
• Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Gilead Sciences, Inc.
• Bristol-Myers Squibb Company
• Pfizer, Inc.
• Novartis AG

Latest Developments

• In December 2023, Pfizer acquired Akero medicines for $7.3 billion, expanding its footprint in the liver disease medicines sector. Akero's primary candidate, efruxifermin, a FGF21 mimic used to treat NASH, has showed good results in Phase 2b trials. This acquisition demonstrates the increasing prominence of NASH in the pharmaceutical industry's pipeline.
• In November 2023, Intercept Pharmaceuticals reported 5-year follow-up results from the POISE trial of Ocaliva (obeticholic acid) in primary biliary cholangitis (PBC) at the American Association for the Study of Liver Diseases (AASLD) annual meeting. The data showed prolonged improvement in liver biochemistry and a lower risk of liver transplantation or mortality, confirming the treatment's long-term efficacy for PBC.
• In January 2024, Alnylam got FDA approval for Givlaari (givosiran), an RNAi therapy for acute hepatic porphyria. This is a substantial progress in the application of RNA interference technology to liver diseases, providing a new therapy option for a rare but severe liver condition. The approval was based on Phase 3 trial data, which revealed a 74% reduction in yearly porphyria attack rates.

Liver Diseases Therapeutics Market, By Category

• Type of Liver Disease:
• Hepatitis
• Non-alcoholic Fatty Liver Disease (NAFLD)
• Alcoholic Liver Disease (ALD)
• Liver Cirrhosis
• Liver Cancer (Hepatocellular Carcinoma)
• Type of Therapy:
• Pharmacotherapy
• Liver Transplantation
• Nutritional and Lifestyle Interventions
• Interventional Procedures
• Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Liver Diseases Therapeutics Market, By Type of Liver Disease

• Hepatitis
• Non-alcoholic Fatty Liver Disease (NAFLD)
• Alcoholic Liver Disease (ALD)
• Liver Cirrhosis
• Liver Cancer (Hepatocellular Carcinoma)

5. Liver Diseases Therapeutics Market, By Type of Therapy

• Pharmacotherapy
• Liver Transplantation
• Nutritional and Lifestyle Interventions
• Interventional Procedures

6. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

7. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

8. Competitive Landscape

• Key Players
• Market Share Analysis

9. Company Profiles

• AbbVie Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Gilead Sciences, Inc.
• Bristol-Myers Squibb Company
• Pfizer Inc.
• Novartis AG
• Johnson & Johnson
• Celgene Corporation
• Samsung Bioepis Co., Ltd.

10. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

11. Appendix

• List of Abbreviations
• Sources and References